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Three decades of genetic research in Alzheimer disease (AD) have substantially broadened our under-
standing of the pathogenetic mechanisms leading to neurodegeneration and dementia. Positional cloning
led to the identification of rare, disease-causing mutations in APP, PSEN1, and PSEN2 causing early-onset
familial AD, followed by the discovery of APOE as the single most important risk factor for late-onset AD.
Recent genome-wide association approaches have delivered several additional AD susceptibility loci that
are common in the general population, but exert only very small risk effects. As a result, a large proportion
of the heritability of AD continues to remain unexplained by the currently known disease genes. It seems likely
that much of this ‘‘missing heritability’’ may be accounted for by rare sequence variants, which, owing to
recent advances in high-throughput sequencing technologies, can now be assessed in unprecedented
detail.Introduction
Alzheimer disease (AD) is the most common neurodegenerative
disease and one of the most common diseases in the industrial-
ized world. Clinically it is defined by a slowly progressing loss of
cognitive functions, ultimately leading to dementia and death.
Neuropathologically it is characterized by the aggregation and
deposition of misfolded proteins, in particular aggregated
b-amyloid (Ab) peptide in the form of extracellular senile
(or neuritic) ‘‘plaques,’’ and hyperphosphorlylated tau (t) protein
in the form of intracellular neurofibrillary ‘‘tangles’’ (NFTs). These
pathognomonic changes are often accompanied by abundant
microvascular damage, including vascular amyloid deposits,
and pronounced inflammation of the affected brain regions.
Genetically, AD is usually divided into two forms: (1) familial
cases with Mendelian inheritance of predominantly early-onset
(<60 years, early-onset familial AD [EOFAD]), and (2) so-called
‘‘sporadic’’ cases with less apparent or no familial aggregation
and usually of later onset age (R60 years, late-onset AD
[LOAD]). It needs to be emphasized that this traditional dichoto-
mization is overly simplistic as there are cases of early-onset AD
without evidence for Mendelian transmission while, conversely,
LOAD is frequently observed with a strong familial clustering,
sometimes resembling a Mendelian pattern. While EOFAD is
caused by rare and highly penetrant mutations in three genes
(see below), the genetics of LOAD is more complex. Current
thinking posits that susceptibility for LOAD is conferred by
numerous genetic risk factors of relatively high frequency but
low penetrance and therefore small effect size (see below). While
LOAD is also sometimes referred to as ‘‘sporadic AD,’’ it is
important to emphasize that up to 60%–80% of this form of
AD is genetically determined (Gatz et al., 2006). Still, environ-
mental and epigenetic factors likely make an important contribu-
tion in determining an individual’s risk, although the precise270 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.nature and mechanisms underlying this nongenetic component
remain largely elusive, in part because they are difficult to assess
experimentally (see also the review by Traynor and Singleton
[2010] in this issue of Neuron).
In this review, we provide a historical as well as quantitative
summary of genetic research in AD. Systematic evaluation of
the aggregated association evidence accumulated in the field
to date (Figure 1) reveals a pronounced distinction between
results from candidate gene versus genome-wide approaches:
during the course of only three years, genome-wide association
studies (GWAS) in AD have yielded more reproducible and
consistent—and thus likely more relevant—findings than three
decades of candidate-gene-driven research. Accordingly, in
this article we will not focus on results from the candidate gene
era (which have been extensively reviewed in the past, e.g.,
Bertram and Tanzi, 2008; Avramopoulos, 2009), but rather on
themost recently implicated GWAS loci in AD, in particular those
that showed evidence for genome-wide significant association
either in individual studies or as a result of systematic meta-anal-
yses. In addition, we discuss the potential relevance of these
loci to AD pathogenesis and provide an outlook of the promises
and limitations of future genetic studies in AD.
Positional Cloning Led to the Discovery of Three
Early-Onset Familial AD Genes
Similar to most other Mendelian diseases, early progress in deci-
phering the genetics of ADwas afforded by studying large, multi-
generational pedigrees suffering from very early-onset forms of
thedisease (EOFAD). Assessing coinheritanceof specific genetic
markers in genetic linkage analyses provided a rough estimate of
themost likely locationof the underlyingdiseasegene,whichwas
subsequently identified by means of ‘‘positional cloning,’’ i.e.,
amore or less systematicmutational screening of DNA segments
Figure 1. Manhattan Plot of Currently Published Genetic Association Findings in AD
Displayed are log(10) p values (y axis) of all polymorphisms (n = 2033) with published genetic data currently available on the AlzGene database (http://www.
alzgene.org; current onSeptember 27, 2010), listed in genomic order (x axis). Greendots represent p values resulting from random-effects allele-basedmeta-anal-
yses ofR four independent data sets using either genotype summary data or effect size estimates provided in the original publications. Black/gray dots represent
either single-study p values or the results ofmeta-analyses on < four independent data sets. Red horizontal line indicates one common threshold for genome-wide
significance (p = 13 107). Note that p values at theAPOE locus actually go below 13 1050 and are truncated here for display purposes. Vertical columns repre-
sent approximate locations of LOAD linkage findings (based on a ‘‘narrow definition’’ of diagnosing AD) as reported in a recent meta-analysis of LOAD linkage
studies (Butler et al., 2009). Dark columns represent regions that showed ‘‘genome-wide suggestive,’’ while light columns showed ‘‘genome-wide nominal’’
evidence for linkage. Genes in blue font represent the approximate locations of the currently knownEOFADgenes. Data fromboth resourceswere scaled to repre-
sent the NCBI36/hg18 build of the human reference genome. The plot was generated in R using ‘‘qqman’’ (http://gettinggeneticsdone.blogspot.com/).
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of three distinct genetic loci—APP (amyloid precursor protein) on
chromosome 21q, PSEN1 (presenilin 1) on 14q, and PSEN2
(presenilin 2, a homolog of PSEN1), on 1q—that cause AD with
high penetrance in mutation carriers (reviewed in Tanzi and
Bertram, 2005). Currently, more than 200 distinct disease-
causing mutations are known across these genes and several
more are discovered each year (for an up-to-date overview see
the AD & FTD Mutation Database [Cruts and Van Broeckhoven,
1998], http://www.molgen.ua.ac.be/admutations/). Concurrent
with a wealth of functional and molecular genetic data, the iden-
tification of these EOFAD genes has significantly informed our
understanding of the pathogenetic mechanisms underlying neu-
rodegeneration in AD, which inmost instances proved to be con-nected to an abnormal production of the Ab peptide, although
some were also found to influence Ab clearance or aggregation
(Murakami et al., 2003; Tsubuki et al., 2003).
Ab is cleaved from APP by the subsequent action of two
enzymes, b- and g-secretase (Cole and Vassar, 2008; Steiner
et al., 2008). Interestingly, the catalytic center of g-secretase is
encoded by the EOFAD genes PSEN1 and PSEN2. This
convergence of genetic and molecular evidence has given
support to the ‘‘amyloid hypothesis,’’ which postulates that the
abnormal production of Ab is the initial step in triggering the
pathophysiological cascade that eventually leads to AD (Glenner
and Wong, 1984; Hardy and Higgins, 1992; reviewed in Tanzi
and Bertram, 2005), and that other neuropathological hallmarks
of AD—hyperphosphorlylated t-protein and neurofibrillaryNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 271
Table 1. Overview of All Published GWAS in AD
GWAS Design Population No. SNPs
No. AD GWAS
(Follow-up)
No. CTRL GWAS
(Follow-up) ‘‘Featured’’ Genes
Grupe et al., 2007 Case-control USA & UK 17,343 380 (1428) 396 (1666) APOE, ACAN, BCR, CTSS,
EBF3, FAM63A**, GALP,
GWA_14q32.13,
GWA_7p15.2, LMNA,
LOC651924, MYH13, PCK1,
PGBD1, TNK1, TRAK2, UBD
Coon et al., 2007;
Reiman et al., 2007
Case-control USA, Netherlands# 502,627 446 (415) 290 (260) APOE, GAB2
Li et al., 2008 Case-control Canada & UK 469,438 753 (418) 736 (249) APOE, GOLM1,
GWA_15q21.2,
GWA_9p24.3
Poduslo et al., 2009 Family-based
& Case-control
USA 489,218 9 (199) 10 (225) TRPC4AP
Abraham et al., 2008 Case-control UKz 561,494 1082 (-) 1239 (1400) APOE, LRAT
Bertram et al., 2008 Family-based USA 484,522 941 (1767) 404 (838) APOE, ATXN1, CD33,
GWA_14q31
Beecham et al., 2009 Case-control USA^ 532,000 492 (238) 496 (220) APOE, FAM113B
Carrasquillo et al., 2009 Case-control USAC 313,504 844 (1547) 1255 (1209) APOE, PCDH11X
Lambert et al., 2009 Case-control Europez 540,000 2035 (3978) 5328 (3297) APOE, CLU (APOJ), CR1
Harold et al., 2009 Case-control USA & EuropeCz 610,000 3941 (2023) 7848 (2340) APOE, CLU (APOJ),
PICALM
Heinzen et al., 2009 (CNV) Case-control USA^ n.g. 331 (-) 368 (-) APOE, CHRNA7
Potkin et al., 2009 Case-control USA (ADNI)y 516,645 172 (-) 209 (-) APOE, ARSB, CAND1,
EFNA5, MAGI2, PRUNE2
Seshadri et al., 2010 Case-control Europe & USACz# 2,540,000 3006 (6505) 22604 (13532) APOE, BIN1, CLU (APOJ),
EXOC3L2, PICALM
Naj et al., 2010 Case-control USA & Europey#^ 483,399 931 (1338) 1104 (2003) APOE, MTHFD1L
Modified after content on the AlzGenewebsite (http://www.alzgene.org; current on September 27th 2010). Studies are listed in order of publication date
(determined by PubMed-ID number). ‘‘Featured Genes’’ are those genes/loci that were declared as ‘‘associated’’ in the original publication, although
criteria for declaring association may vary across studies; genes underlined and in bold font were reported to show experiment-wide ‘‘genome-wide
significant’’ association; inmany studies, surrogatemarker were used forAPOE.Numbers of ‘‘ADCases’’ and ‘‘Controls’’ refers to sample sizes used in
initial GWAS screening, whereas ‘‘Follow-up’’ refers follow-up data sets (where applicable); please consult AlzGene website for more details on these
studies. Symbols (C, z, #, y, ^) indicate sample overlap across studies with identical symbols. **This locus was originally named ‘‘THEM5.’’
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Reviewtangles, vascular damage, and inflammation—are conse-
quences, rather than causes, of the disease process. The
amyloid hypothesis has also informed the search for and func-
tional interpretation of genetic factors in LOAD (see below).While
the three currently known EOFAD genes explain a large propor-
tion of theMendelian forms of AD, they do not explain all, making
it likely that additional EOFAD-causing genes exist, which—if
identified—could provide novel and valuable insights into the
pathogenesis of AD.
Candidate Gene Studies in AD
The fact that most currently known EOFAD genes cause AD by
an abnormal production of the Ab peptide led to the formulation
of other Ab-centered hypotheses in the search for the genetic
causes of LOAD (e.g., with potential effects on Ab production,
aggregation, or clearance; Table 2). One of the first such ‘‘candi-
date genes’’ assessed for genetic association with AD was
APOE (encoding apolipoprotein E [apoE]) on chromosome
19q13. Since the APOE-containing chromosomal region was272 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.implied by means of genetic linkage analysis before any bona
fide association studies were conducted (Pericak-Vance et al.,
1991), APOE was a candidate gene on both functional and posi-
tional grounds, a convergence that has (re)emerged for some of
the most recently implicated LOAD genes (Figure 1). The original
discovery that the 34 allele of a 3 allele haplotype (composed of
32, 33, and 34 alleles, which show different biochemical proper-
ties at the protein level) leads to a dose-dependent increase in
AD risk of 4-fold as compared to noncarriers (Strittmatter
et al., 1993) has been replicated in essentially all independent
follow-up studies (Bertram et al., 2007). The association between
increased risk for AD and 34 continues to be—by a margin—the
lead association finding even in modern-days genetic studies of
LOAD (Table 1). In contrast to 34, the rarer 32 allele appears to
exert ‘‘protective’’ effects (or ‘‘healthier aging’’) when inherited
with the 33 allele as compared to homozygous 33 allele carriers
(Corder et al., 1994; Gerdes et al., 2000), a finding that has
been consistently replicated, albeit at lower statistical signifi-
cance (Farrer et al., 1997).
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several pieces in the puzzle of Ab-centered AD hypotheses
(Table 2), and a detailed discussion of the wealth of in vitro and
in vivo evidence supporting its role in AD pathogenesis is beyond
the scope of this review (for recent reviews, see Kim et al., 2009a,
and Vance and Hayashi, 2010). However, despite the broad
molecular evidence that apoE protein is involved in AD-specific
pathways, it is interesting that genetic variation in the APOE
gene has also been associated with risk for numerous other
neuropsychiatric disorders including Parkinson disease (Lill
et al., 2010b; Williams-Gray et al., 2009) and multiple sclerosis
(Lill et al., 2010a), as well as a number of cardio- and cerebrovas-
cular diseases (Peck et al., 2008; Willer et al., 2008), age-related
macular degeneration (Bojanowski et al., 2006), and longevity
(Sebastiani et al., 2010; Gerdes et al., 2000). It should be noted,
however, that different alleles are associated with disease risk
across different phenotypes and none of these associations is
nearly as well established as APOE’s effects on AD risk. Func-
tionally, all of the aforementioned putative associations could
at least partially relate to apoE’s pivotal role in lipid and choles-
terol metabolism (Zhang et al., 1992).
The nonspecific nature of the APOE-AD association has
prompted several investigators to propose that the actual AD-
predisposing effect may be exerted by other genes/proteins in
the chromosomal interval containing APOE (Takei et al., 2009;
Roses et al., 2010). The latter study identified a polymorphic
poly-T variant in TOMM40 (encoding translocase of outer mito-
chondrial membrane 40 homolog; which maps only 2,000 bp
proximal of APOE), of which ‘‘long’’ poly-T repeats are associ-
ated with a younger onset age even in 33 allele carriers as
compared to ‘‘short’’ poly-T repeats. If confirmed in independent
data sets, this finding could explain why the 34 allele in APOE
does not account for all of the genetic variance attributed to
the chromosome 19q13 region in LOAD. In addition, it was
recently proposed that genetic variants in or near the EXOC3L2
(exocyst complex component 3-like 2) gene (300 kb distal of
APOE) may have an effect on AD risk that is independent of 34
(Seshadri et al., 2010). Unfortunately, systematic assessment
of the possible genotype-phenotype correlations in the chromo-
somal interval containingAPOE is aggravated by the fact that the
SNPs defining the 32/3/4 haplotypes are only poorly covered by
current genome-wide microarrays, necessitating manual rege-
notyping in most instances (Thompson et al., 2009).
The early success of the candidate gene approach in AD has
spurred a large number of genetic association studies assessing
other loci of potential relevance based on functional hypotheses
(mostly Ab-centered). The outcomes have been inconsistent; of
the nearly 700 candidate AD genes investigated over the past
30 years, only few show significant risk effects when data from
all available studies are combined (Bertram and Tanzi, 2008)
(for an up-to-date overview see the AlzGene Database). Note-
worthy examples include associations seen with common
variants in ACE (angiotensin-converting enzyme; Kehoe et al.,
1999), ADAM10 (disintegrin and metalloproteinase domain-con-
taining protein 10; Kim et al., 2009b), CHRNB2 (cholinergic
receptor, nicotinic, beta 2; Cook et al., 2004), DAPK1 (death-
associated protein kinase 1; Li et al., 2006), IL8 (interleukin 8;
Li et al., 2009), MTHFR (methylenetetrahydrofolate reductase;Chapman et al., 1998), OTC (ornithine carbamoyltransferase;
Bensemain et al., 2009), SORL1 (sortilin-related receptor;
Rogaeva et al., 2007), and TF (transferrin; van Rensburg et al.,
1993), which all show modest genetic effects but only modest
statistical support in random-effects meta-analyses. While the
modest effect sizes exerted by these candidate loci (i.e., odds
ratios [OR] between 1.15 and 1.5) are quite typical for geneti-
cally complex diseases, their statistical support (i.e., p values
between 0.0001 and 0.01) is orders of magnitude below (i.e.,
less significant) that observed for loci that have recently emerged
from GWAS in AD (i.e., p values << 13 107, Figure 1). This can
be attributed to a number of reasons likely acting in combination,
including type-I error, small sample size, and different sources of
bias (Ioannidis, 2005). It is interesting to note that the candidate
gene approach was substantially more successful in identifying
robust disease associations in some other disorders, such as
Parkinson disease (PD), where the lead susceptibility signals
(SNCA [a-synuclein], MAPT [microtubule-associated protein
tau], LRRK2 [leucine-rich repeat kinase 2], GBA [glucosidase,
beta, acid]) were already established with genome-wide signifi-
cance years before the GWAS era (Lill et al., 2010b; Ross and
Farrer, 2010). Another surprising difference between AD and
PD is that two of the genes established to cause autosomal-
dominant forms of PD (SNCA and LRRK2) also show unequiv-
ocal and highly significant risk effects on non-Mendelian
(‘‘idiopathic’’) PD, while no such correlation appears to exist in
AD for APP, PSEN1, and PSEN2 (AlzGene database). Further-
more, MAPT (encoding t-protein, the abnormal deposition of
which represents a neuropathological hallmark for AD but not
PD) is highly significantly associated with risk for PD (p = 3.6 3
1021), but currently not AD.
Genome-wide Association Studies in AD
One of the main limitations of the candidate gene approach is
its focus on a preconceived functional and/or positional hypoth-
esis. Until recently, this approach was aggravated by technical
limitations, as it was both laborious and expensive to develop
multiplex genotyping assays that allowed for investigation of
more than a fewmarkers at a time. In the last five years, however,
the advent of microarray technology has revolutionized genetics
research, and it is now possible to assess several hundreds of
thousands (or via in silico genotyping, or imputation, several
millions) of single-nucleotide polymorphisms (SNPs) in one
experiment. Usually, SNPs on these microarrays are inter-
spersed at high density throughout all chromosomes, effectively
allowing one to perform genome-wide association testing in a
largely hypothesis-free manner, e.g., as GWAS. While genome-
wide screening has distinct advantages,massivemultiple testing
is a critical issue and substantially more rigorous criteria are
required to declare an association as being ‘‘significant’’ on an
experiment-wide level. Several thresholds to declare genome-
wide significance have been proposed, with p values usually
ranging between 5 3 107 and 5 3 108 (Ioannidis et al., 2009;
McCarthy et al., 2008), although there are other ways to deter-
mine study-specific genome-wide significance (Ionita-Laza
et al., 2007).
Several GWAShave been performed in AD to date (Table 1). All
but one have seen APOE as the by far most significant findingNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 273
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Review(with p values down to13 10160; Harold et al., 2009), but over
three dozen other loci beyond APOE have been implicated
(Table 1). Of these, only a few were reported to show study-
specific genome-wide significance in at least one report, and
only these loci will be discussed in chronological order in the
remainder of this section.
The first genome-wide significant finding was reported for
GAB2 (GRB2-associated binding protein 2) by Reiman et al.
(2007), who found this effect to be most pronounced in carriers
of the 34 allele at APOE. This finding has been met with mixed
replications (e.g., Chapuis et al., 2008; Sleegers et al., 2009)
and currently shows a p value of 2.2 3 103 in the ongoing
AlzGene meta-analyses. It also showed nonsignificant (p value
0.15) effect sizes in the same direction as in the original report
in a large subsequently published GWAS (Harold et al., 2009),
although no further details were given. Functionally, GAB2
protein may be involved in the production of Ab as it binds to
Grb2 (growth factor receptor-bound protein 2), which in return
can bind APP and both presenilins (Nizzari et al., 2007). Other
data also suggest a potential involvement in tau phosphorylation
and NFT formation (Reiman et al., 2007).
The second genome-wide significant association signals were
reported by Bertram et al. (2008), in a family-based GWAS for
ATXN1 (ataxin 1), CD33 (siglec 3), and an as yet uncharacterized
locus on chromosome 14 (GWA_14q31.2). While for the latter,
current AlzGenemeta-analyses show no support of independent
replication in case-control data sets (e.g., Bettens et al., 2009),
only insufficient data exist to merit meta-analyses for the other
two loci (although Harold et al. [2009] reported no evidence for
association with either of these genes). Functional genetic
experiments suggest that differences in ATXN1 expression can
modulate Ab levels in vitro, an effect that appears to bemediated
via b-secretase cleavage of APP (Zhang et al., 2010). CD33
belongs to the family of sialic acid-binding, immunoglobulin-
like lectins that are believed to promote cell-cell interactions
and to regulate the functions of cells in the adaptive and innate
immune systems (Crocker et al., 2007; von Gunten and Simon,
2006), both involved in contributing to the inflammatory reac-
tions observed in the brains of AD patients. In this context it is
interesting to note recent data suggesting that Ab could function
as an antimicrobial peptide that may have a normal function in
the innate immune system (Soscia et al., 2010).
In 2009, several AD GWAS were published suggesting the
presence of additional AD susceptibility genes. First, Carra-
squillo et al. (2009), highlighted PCDH11X (protocadherin 11
X-linked), currently the only GWAS signal on the X chromosome.
Just like several other loci discussed in this section, independent
replication of this finding has been inconsistent (e.g., Beecham
et al., 2010). Some protocadherins have been proposed as
g-secretase substrates (Haas et al., 2005), and it remains to
be seen whether or not PCDH11X competes with APP for g-sec-
retase.
Later that year, two large GWAS from the UK (Harold et al.,
2009) and France (Lambert et al., 2009) were published back-
to-back highlighting three novel AD genes, i.e., CLU (clusterin;
a.k.a. apolipoprotein J), CR1 (complement component (3b/4b)
receptor 1), and PICALM (phosphatidylinositol binding clathrin
assembly protein). All three of these loci have since received274 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.overwhelming support from independent follow-up studies
(Carrasquillo et al., 2010; Jun et al., 2010; Schjeide et al., in
press) and currently rank at the very top of the AlzGene meta-
analyses, directly following APOE. All three loci show genome-
wide significant association in allelic meta-analyses combining
all available data with p values ranging from 2.1 3 1020 (CLU;
rs11136000), 2.7 3 108 (CR1; rs3818361), and 1.1 3 1016
(PICALM; rs3851179; Figure 1). In addition, there are several
other SNPs in each of these loci showing highly significant asso-
ciation (p values < 1 3 105) with AD risk, leaving essentially no
doubt that variants in these or nearby genes represent genuine
AD susceptibility loci. Furthermore, it is interesting to note
that—like APOE—two of these novel AD loci map in or close to
regions showing strong evidence for LOAD linkage in a recent
meta-analysis of genome-wide linkage studies (Butler et al.,
2009), i.e., CLU on chromosome 8p21 and CR1 on 1q32.2 (Fig-
ure 1). Despite their strong statistical support, it should be
emphasized that the effect sizes exerted by these loci are
collectively low (allelic ORs 1.15 for all three loci), which is
much less than for APOE 34 (allelic OR 4) or other established
neurodegenerative disease loci (e.g., ORs > 1.3 for three of the
established Parkinson susceptibility loci—SNCA, MAPT, and
LRRK2—which were all confirmed by different GWAS; Pankratz
et al., 2009; Simo´n-Sa´nchez et al., 2009; Satake et al., 2009).
Functionally, the novel loci implicated by Harold et al. (2009)
and Lambert et al. (2009) may exert their effects in a number of
ways (Table 2). Clusterin is a 75 kDa chaperone molecule
that is expressed in all tissues, including the CNS. The main
associated SNP (rs11136000) lies deeply intronic with no known
or implied functional effect. In addition to possibly being involved
in clearance and aggregation of Ab, clusterin has also been
reported to be involved in Ab fibrillization (DeMattos et al.,
2002, 2004), regulation of brain cholesterol and lipidmetabolism,
and the inhibition of neuronal apoptosis/potentiation of neuro-
protection (Nuutinen et al., 2009). CR1 is the main receptor of
the complement C3b protein, a key inflammatory protein acti-
vated in AD (Khera and Das, 2009; Wyss-Coray et al., 2002). In
vitro and in vivo experiments suggest that complement activa-
tion can protect against Ab-induced neurotoxicity and may
reduce the accumulation/promote the clearance of amyloid
and degenerating neurons (Rogers et al., 2006; Wyss-Coray
et al., 2002). PICALM plays a role in clathrin-mediated endocy-
tosis (Tebar et al., 1999), synaptic transmission, and the removal
of apoptotic cells (Harel et al., 2008; Yao et al., 2005). With
respect to AD it is interesting that the C-terminal fragment of
APP generated by b-secretase cleavage undergoes clathrin-
mediated endocytosis before being cleaved by g-secretase
(Koo and Squazzo, 1994). It is therefore possible that dysfunc-
tional PICALM protein could interfere with this process, but
this notion has not been supported by preliminary in vitro studies
(Wu et al., 2009). Furthermore, brain-expressed PICALM protein
is predominately expressed in endothelial cells, where it could
play a role in Ab transport into the bloodstream (Baig et al.,
2010). The hypothesis that PICALMmay be involved in Ab clear-
ance is also supported by recent data indicating that—like APOE
34—the PICALM risk allele is associated with reduced levels of
Ab in the cerebrospinal fluid of AD patients and control individ-
uals (Schjeide et al., in press).
Table 2. Potential Mechanisms Linking Genome-wide Association Findings to AD Pathogenesis
APOE ATXN1 BIN1 CD33 CLU CR1 GAB2 PCDH11X PICALM
Ab-production Zhang et al.,
2010
Wigge et al.,
1997;
Pant et al.,
2009
Nizzari et al.,
2007
Haas et al.,
2005
Tebar et al.,
1999
Ab-aggregation Kim et al.,
2009a;
Moir et al.,
1999
DeMattos et al.,
2002;
Thambisetty et al.,
2010
Ab-clearance Kim et al.,
2009a;
Holtzman et al.,
1999
Wigge et al.,
1997;
Pant et al.,
2009
Zlokovic et al.,
1996;
DeMattos et al.,
2004
Wyss-Coray et al.,
2002;
Rogers et al.,
2006
Tebar et al.,
1999;
Baig et al.,
2010
t-phosphorylation Reiman et al.,
2007
Synaptic
transmission
Senzaki et al.,
1999;
Blanco et al.,
2000
Yao et al.,
2005;
Harel et al.,
2008
Inflammation Kim et al.,
2009a
Crocker et al.,
2007;
von Gunten
and Simon,
2006
Xie et al., 2005 Wyss-Coray et al.,
2002; Khera
and Das,
2009
Cerebrovascular
events
Kim et al., 2009a
Schematic overview of the potential functional impact of GWAS findings and their reported or suggested potential involvement in a number of pathogenetic pathways of relevance to AD. Only
signalsmapping to known genes and reported to show genome-wide significance for association with AD in at least one study are included in this table. References listed in intersecting cells point
to a selection of both primary and review publications on the proposed pathomechanisms (only 1–2 representative publications are selected per example). Note that some pathomechanisms
(e.g., Ab-degradation; t-aggregation) have currently not been linked to any of the proposed GWAS loci; conversely, no hypotheses or data with respect to the potential impact of EXOC3L2 or
MTHFD1L on AD pathogenesis have been published to date which is why they are not listed in this table.
N
e
u
ro
n
6
8
,
O
c
to
b
e
r
2
1
,
2
0
1
0
ª
2
0
1
0
E
ls
e
v
ie
r
In
c
.
2
7
5
N
e
u
ro
n
R
e
v
ie
w
Neuron
ReviewIn 2010, two further GWAS were published suggesting the
existence of three additional AD susceptibility loci. The first
(Seshadri et al., 2010) resulted from a large collaborative effort
that also included the GWAS data from four of the five aforemen-
tioned studies (Table 1). In addition to replicating the association
between CLU and PICALM—which was not unexpected given
that a large proportion of samples overlapped with the GWAS
that originally implicated these genes—this study highlighted
two potential additional AD risk factors, i.e., BIN1 (bridging
integrator 1; originally implicated at subgenome-wide signifi-
cance by Harold et al. [2009]) and EXOC3L2 (exocyst complex
component 3-like 2), or a locus nearby on chromosome
19q13.32. Combining all available data, both genes currently
display highly significant association with AD risk on AlzGene
with p values around 3.0 3 1010 and 2.1 x 1010, respectively
(Figure 1), and allelic ORs in the order of1.15.BIN1 (also known
as amphiphysin II) encodes several isoforms of an adaptor
protein involved in receptor-mediated endocytosis (Pant et al.,
2009; Wigge et al., 1997), which—as hypothesized for PIC-
ALM—could have an effect on Ab production and/or the
clearance of Ab from the brain. In addition, rare, homozygous
mutations inBIN1 have been found to cause recessive centronu-
clear myopathy, a condition characterized by muscle weakness
and abnormal centralization of nuclei in muscle fibers (Nicot
et al., 2007). The disease-causing effect is probably triggered
by abrogating BIN1’s interaction with dynamin 2, which has
also been associated with risk for LOAD in candidate gene
analyses (Aidaralieva et al., 2008), albeit inconsistently. The
biological function of the protein encoded by EXOC3L2
remains largely elusive. It should be emphasized, however,
that the 100 kb region harboring the risk-associated variant
(rs597668) on chromosome 19q13.32 contains several other
genes (e.g.,NKPD1 [NTPase, KAP family P loop domain contain-
ing 1], TRAPPC6A [trafficking protein particle complex 6A],
BLOC1S3 [biogenesis of lysosomal organelles complex-1,
subunit 3],MARKL1 [MAP/microtubule affinity-regulating kinase
4], and MARK4 [MAP/microtubule affinity-regulating kinase 4]),
which could also represent the functional correlates underlying
this association. It is also noteworthy that the associated SNP
only maps 300 kb distal to the APOE region, so it remains to
be seen whether these two regions are genetically/functionally
related. It also is quite possible that rs597668 ismerely ‘‘tagging’’
the association with APOE and does not actually represent
a novel AD locus in its own right.
The latest addition to the set of GWAS-derived putative LOAD
loci is MTHFD1L (methylenetetrahydrofolate dehydrogenase
[NADP+ dependent] 1-like), recently reported to show genome-
wide significant association with AD risk in 5,000 individuals
(Naj et al., 2010). In contrast to most other AD GWAS findings,
the risk allele at the associated SNP (rs11754661) appears
to confer relatively large effect sizes, i.e., allelic ORs 2, which
translates into nearly doubling the risk for AD in carriers of
the minor allele. The study was an extension of this group’s
earlier GWAS (Beecham et al., 2009), which had already previ-
ously implicated this locus at genome-wide suggestive signifi-
cance. As such, it was included in auxiliary analyses of the
GWAS by (Harold et al., 2009), who reported no evidence of
association with SNP rs11754661 in their sample (OR = 1,276 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.p = 0.98), despite excellent power to detect the proposed OR
of 2.
In summary, GWAS have substantially reshaped the land-
scape of LOAD genetics during the course of only three years.
Currently, the most promising findings relate to the identification
of variants in or near BIN1, CLU, CR1, and PICALM whose
status as novel AD risk loci have been confirmed by extensive
and independent replication data. Other GWAS loci, such as
ATXN1, CD33, EXOC3L2, GAB2, MTHFD1L, and PCDH11X,
should be considered more provisional until further replication
data become available. While fine-mapping and biochemical
studies are still needed to identify the sequence variants under-
lying the currently observed genetic associations and to confirm
and characterize their presumed molecular effects, nearly all of
the newly reported GWAS loci have been linked to Ab metabo-
lism in one or more ways (Table 2). In particular, this relates to
Ab-aggregation or clearance of Ab from the brain either directly
or indirectly, e.g., via effects on the immune system response
to Ab-related toxicity. However, these potential, Ab-centered
functional connections are still preliminary in most instances,
and further research is needed to clarify whether or not other
pathways are affected by these loci. Furthermore, it can be
expected that several additional AD susceptibility variants will
be identified in future genome-wide efforts using higher-density
microarrays in combination with substantially increased sample
sizes, alternative phenotype definitions (e.g., ‘‘endophenotypes’’
such as neuroimaging or CSF biomarker levels), and via system-
atic data-integration and meta-analysis efforts. It remains to be
seen whether these findings will reveal hitherto unrecognized,
novel pathogenetic mechanisms beyond those related to the
metabolism of APP and Ab.
Back to the Future: Beyond GWAS and the Search
for Causal Variants
Despite the enthusiasm revolving around the novel GWAS find-
ings, it should not be forgotten that, individually, the risk effects
exerted by the new GWAS loci are small, i.e., they confer a mere
0.10-fold to 0.15-fold increase or decrease in AD risk in carriers
versus noncarriers of the associated alleles, compared to
a nearly 4-fold increase in AD risk related to the presence of
the APOE 34 allele. Although to date no precise estimate exists
regarding the proportion of LOAD heritability explained by the
combined effects of APOE and the confirmed GWAS loci,
it appears reasonable to assume that this proportion does not
exceed 50%. This is the upper bound of explained heritability
in other complex diseases for which—unlike AD—significant
association has been demonstrated for several common loci of
large effect (i.e., ORs > 2 to > 3), such as age-related macular
degeneration (Chen et al., 2010; Manolio et al., 2009). In other
words, a substantial proportion of the heritability for LOAD likely
remains unexplained by the currently known susceptibility
genes. The ‘‘missing heritability’’ in these traits has been coined
as the ‘‘dark matter’’ of GWAS, in the sense that ‘‘one is sure it
exists, can detect its influence, but simply cannot see it (yet)’’
(Manolio et al., 2009).
There are four main areas likely to account for the missing
heritability in AD: (1) common variants that are inappropriately
tagged by any of the existing microarrays; (2) common variants
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effects than the ones already identified (i.e., ORs < 1.1) and
can only be identified in very large sample sizes (for AD this
would require between 25,000 and > 100,000 combined
cases and controls for allele frequencies ranging between 0.5
and 0.05, respectively, to be detected at genome-wide signifi-
cance, i.e., p values 1 3 107); (3) copy-number variants
and structural chromosomal changes (while these can be
resolved to a certain degree on existing GWAS microarrays,
this has only rarely been carried out for AD to date, see Table
1); (4) rare sequence variants (e.g., with minor allele frequencies
<< 5%) conferring both small and large effects. While the
former three issues can be addressed by upcoming GWAS,
current microarray technology is not designed for de novo
identification or the reliable measurement of rare sequence
variants. As a matter of fact, owing to this inherent limitation,
most GWAS analysis pipelines explicitly exclude rare variants
(e.g., MAFs < 5% or < 1%) prior to analysis. Thus, the identifi-
cation of the presumed disease-associated rare variants will
require deep resequencing in suitable data sets, either small
scale (i.e., restricted to specific loci, e.g., previously associated
GWAS regions, similar to what has been done for years in
positional cloning and candidate gene experiments) or large
scale (e.g., whole exome, or whole genome). The genetics
community has already begun to construct a comprehensive
catalog of rare sequence variants in the human genome by
applying large-scale resequencing using recently developed,
massively parallel (so called ‘‘next-generation’’) sequencing
techniques, e.g., as part of the 1000 Genomes project (http://
www.1000genomes.org/). For the most part, however, this will
not alleviate the need to actually directly test these variants in
sufficiently large collections of affected and unaffected individ-
uals in disease-centered discovery projects.
As for all previous eras of human genetic research (i.e., posi-
tional cloning, candidate gene, GWAS), the specific disease-
causing or disease-modifying effects can only be established
following in-depth functional genetic characterization of the
associated variants, followed by validation in patient materials
and/or relevant animal models. While this molecular evidence
has proven immensely difficult to attain for most common
variants of small effect, the functional characterization of the
rare, EOFAD-causing mutations in APP, PSEN1, and PSEN2
has been pivotal for our understanding of AD pathogenesis.
This can be attributed to the fact that most EOFAD mutations
engender amino acid changes with clear functional conse-
quences on Ab metabolism. In contrast, common disease-
associated variants often lie in genomic regions of no obvious
functional consequence, e.g., gene deserts, or deep within
introns. Based on the sheer number of potentially functional
coding region variants to emerge from deep resequencing
efforts over the coming years, much of the progress in the field
will depend on the development of appropriate and efficient
in silico and in vitro high-throughput pipelines to study variant-
activity relationships in a systematic manner.
It goes beyond the scope of this review to provide a detailed
account of the various available approaches for the generation
and analysis of large-scale resequencing data aimed at identi-
fying rare variants linked to disease. However, several landmark,proof-of-principle projects have already been completed that
can be regarded as initial reference (reviewed in Manolio et al.,
2009; McClellan and King, 2010). These studies succeeded not
only to identify novel disease-causing variants of Mendelian
diseases in genes previously unlinked to the specific traits
(Bilgu¨var et al., 2010; Gilissen et al., 2010; Ng et al., 2010), but
also to ‘‘resolve’’ the complex patterns that typically emerge
from GWAS approaches (Dickson et al., 2010; Johansen et al.,
2010; Nejentsev et al., 2009), althoughmost of these findings still
await functional genetic confirmation and characterization.
It does not seem too far-fetched to expect that in AD, as well,
such efforts will revolutionize our understanding of the true
genetic forces underlying disease susceptibility, possibly more
so than GWAS have begun to expand our knowledge about
the genetic basis of LOAD beyond APOE.
A continuing challenge in the coming years will be to efficiently
distinguish between findings that likely reflect genuine genetic
effects versus those that are simply due to chance. For common
variants, i.e., those typically assayed in candidate gene or GWAS
approaches, several guidelines have already been suggested
(e.g., Chanock et al., 2007; Little et al., 2009; Khoury et al.,
2009) that essentially amount to demonstrating genome-wide
significance upon combining results from all available data
sets (e.g., via meta-analysis) in the absence of significant hetero-
geneity or bias. For variants with only insufficient support
(e.g., those showing nominal association but lacking power to
achieve genome-wide significance), intermediate measures
have been proposed that may help to assess the ‘‘solidity’’ of
a finding until sufficient data are available (e.g., using Bayesian
analyses to estimate the odds that a finding is ‘‘real’’ [Wellcome
Trust Case Control Consortium, 2007; Wakefield, 2007], or
grading its ‘‘epidemiologic credibility’’ [Ioannidis et al., 2008]).
For rare variants, the situation is more complex for a number of
reasons, including the need for very large sample sizes (owing
to the low allele frequencies), or confounding due to allelic
heterogeneity (i.e., different alleles in the same gene that
contribute independent risk effects). Several approaches have
been suggested to overcome these issues, e.g., to pool variants
within the same coding regions (Price et al., 2010) or to measure
general ‘‘mutational load’’ in case versus control subjects
(International Schizophrenia Consortium, 2008). A crucial factor
in this context will be to distinguish between rare variants with
disease-specific effects from neutral coding changes, e.g., by
means of high-throughput functional assays and/or by studying
pedigrees rather than unrelated cases and controls to prove
cosegregation with disease status.
Conclusions
Three decades of genetic research in AD have substantially
broadened our understanding of the pathogenetic mechanisms
leading to neurodegeneration and dementia. Initially, genetic
linkage analysis followed by positional cloning identified the
major causes underlying EOFAD by pinpointing rare, disease-
causing mutations in APP, PSEN1, and PSEN2. Candidate
gene approaches, sometimes informed by genetic linkage
results, have led to the discovery of APOE as the single most
important risk factor for LOAD. Recently, GWAS have delivered
several additional susceptibility loci that are common in theNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 277
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Reviewgeneral population, but only exert very small genetic effects.
Several other common risk-factor genes can be expected to
emerge from GWAS in the coming years. Collectively, however,
a large proportion of the heritability of AD will continue to remain
unexplained by the variants invoking these association signals.
It seems likely that much of the ‘‘missing heritability’’ may be
caused by rare sequence variants in genes that predispose to
both early- and late-onset forms of AD.
For the first time in the history of human genetics research, the
genetic basis of AD and other heritable diseases can be
assessed in unprecedented detail and efficiency owing to recent
advances in large-scale sequencing technologies. Our initial
understanding of the etiology of AD began with the identification
of rare causal mutations in EOFAD. As we commence to engage
in large-scale resequencing projects, we may very well find
ourselves ‘‘back to the future’’ by discovering rare causal
variants in genes that were initially associated with AD based
on common SNPs appearing to exert only small effects on
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